Monoclonal antibodies have become a critical and effective therapeutic approach in cancer treatment due to their specific targeting ability toward molecules. However, owing to the complex pathogenic mechanisms of cancer, monoclonal antibodies targeting a single point struggle to demonstrate sufficient therapeutic efficacy. In this context, bispecific antibodies have emerged.

（Molecular format example）

Bispecific antibodies bind to two or more different antigens, opening up new therapeutic applications that traditional monoclonal antibodies cannot achieve. They facilitate redirecting drugs to the local tumor, enhancing binding specificity, improving the accuracy of drug targeting to tumor cells, and reducing off-target toxicity. Mabnus Biotech's extensive experience in bispecific antibody projects allows us to design and express various forms of bispecific antibodies for our clients. Starting from hybridoma cell lines or antibody sequences, we can provide customized bispecific antibodies ranging from milligrams to grams.